Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric maltol - Shield Therapeutics

Next Previous
Drug Profile

Ferric maltol - Shield Therapeutics

Alternative Names: ACCRUFeR; Accrufer; FeRACCRU; Feraccru; Iron (III) maltol; ST-10; ST10-021

Latest Information Update: 08 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Cambridge; University of London
  • Developer Beijing Aosaikang Pharmaceutical; KYE Pharmaceuticals; Norgine; Shield Therapeutics
  • Class Antianaemics; Ferric compounds; Pyrones; Small molecules
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 03 Mar 2026 Phase-III clinical trials in Iron deficiency anaemia (In adolescents, In adults, In children) in China (PO)
  • 03 Mar 2026 Preregistration for Iron deficiency anaemia (In adults, In adolescents, In children) in China (PO)
  • 03 Mar 2026 Chinese NMPA accepts Marketing Authorisation Application for Ferric maltol for Iron deficiency anaemia for review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top